



PRESS RELEASE, NOVEMBER 14, 2014

## Moberg Pharma changes in Board of Directors

**Moberg Pharma AB (OMX: MOB) announces that, effective as of today, George E. Aitken-Davies has resigned from the Board of Directors of Moberg Pharma in conjunction with the final earn-out payment related to the acquisition of Alterna LLC in 2012. Appointed by Altaris Capital Partners, George E. Aitken-Davies remains a member of the Nomination Committee of Moberg Pharma until the Annual General Meeting in May 2015.**

*"I would like to thank George for his valuable contributions to the board at Moberg Pharma. The acquisition in 2012 of Moberg Pharma North America (previously Alterna LLC), a former portfolio company of Altaris Capital Partners, has been a success and today represents two thirds of the sales of Moberg Pharma,"* said Peter Wolpert, CEO of Moberg Pharma AB.

### **For additional information contact:**

Peter Wolpert, CEO  
Telephone: +46 (0)70 - 735 71 35  
E-mail: [peter.wolpert@mobergpharma.se](mailto:peter.wolpert@mobergpharma.se)

Peter Östling, IR  
Mobil: +46 (0)76 – 314 09 78  
Email: [peter.ostling@mobergpharma.se](mailto:peter.ostling@mobergpharma.se)

### **About this information**

Moberg Pharma discloses this information pursuant to the Swedish Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 8.30 pm (CET) on November 14, 2014.

### **About Moberg Pharma**

Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with a direct sales and marketing organization in the U.S. and an extensive distributor network in more than 40 countries. The company's OTC portfolio includes the brands Kerasal®, Jointflex®, Kerasal Nail®, Domeboro®, Vanquish®, and Fergon®. Kerasal Nail® (Nalox™ in certain ex-U.S. markets) is the leading product for the treatment of nail disorders in the U.S. and Nordic market. The current portfolio will be supplemented by the acquisition and in-licensing of additional products as well as product development with a focus on innovative drug delivery of proven compounds. Moberg Pharma has offices in Stockholm and New Jersey and the company's shares (OMX: MOB) are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm. For further information, please visit: [www.mobergpharma.com](http://www.mobergpharma.com).